<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>25(10)</volume><submitter>Danchin N</submitter><pubmed_abstract>Background Little is known about the achievement of low density lipoprotein cholesterol (LDL-C) targets in patients at cardiovascular risk receiving stable lipid-lowering therapy (LLT) in countries outside Western Europe. Methods This cross-sectional observational study was conducted in 452 centres (August 2015-August 2016) in 18 countries in Eastern Europe, Asia, Africa, the Middle East and Latin America. Patients ( n = 9049) treated for ≥3 months with any LLT and in whom an LDL-C measurement on stable LLT was available within the previous 12 months were included. Results The mean±SD age was 60.2 ± 11.7 years, 55.0% of patients were men and the mean ± SD LDL-C value on LLT was 2.6 ± 1.3 mmol/L (101.0 ± 49.2 mg/dL). At enrolment, 97.9% of patients were receiving a statin (25.3% on high intensity treatment). Only 32.1% of the very high risk patients versus 51.9% of the high risk and 55.7% of the moderate risk patients achieved their LDL-C goals. On multivariable analysis, factors independently associated with not achieving LDL-C goals were no (versus lower dose) statin therapy, a higher (versus lower) dose of statin, statin intolerance, overweight and obesity, female sex, neurocognitive disorders, level of cardiovascular risk, LDL-C value unknown at diagnosis, high blood pressure and current smoking. Diabetes was associated with a lower risk of not achieving LDL-C goals. Conclusions These observational data suggest that the achievement of LDL-C goals is suboptimal in selected countries outside Western Europe. Efforts are needed to improve the management of patients using combination therapy and/or more intensive LLTs.</pubmed_abstract><journal>European journal of preventive cardiology</journal><pagination>1087-1094</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6039862</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).</pubmed_title><pmcid>PMC6039862</pmcid><pubmed_authors>ICLPS Investigators</pubmed_authors><pubmed_authors>Cuneo CA</pubmed_authors><pubmed_authors>Santos RD</pubmed_authors><pubmed_authors>Blom D</pubmed_authors><pubmed_authors>Mercier F</pubmed_authors><pubmed_authors>Kaul U</pubmed_authors><pubmed_authors>Danchin N</pubmed_authors><pubmed_authors>Karpov Y</pubmed_authors><pubmed_authors>Ruiz AJ</pubmed_authors><pubmed_authors>Berrah A</pubmed_authors><pubmed_authors>Azuri J</pubmed_authors><pubmed_authors>Kayıkcıoglu M</pubmed_authors><pubmed_authors>Mitchenko O</pubmed_authors><pubmed_authors>Aguilar Salinas CA</pubmed_authors><pubmed_authors>Al-Rasadi K</pubmed_authors><pubmed_authors>Almahmeed W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).</name><description>Background Little is known about the achievement of low density lipoprotein cholesterol (LDL-C) targets in patients at cardiovascular risk receiving stable lipid-lowering therapy (LLT) in countries outside Western Europe. Methods This cross-sectional observational study was conducted in 452 centres (August 2015-August 2016) in 18 countries in Eastern Europe, Asia, Africa, the Middle East and Latin America. Patients ( n = 9049) treated for ≥3 months with any LLT and in whom an LDL-C measurement on stable LLT was available within the previous 12 months were included. Results The mean±SD age was 60.2 ± 11.7 years, 55.0% of patients were men and the mean ± SD LDL-C value on LLT was 2.6 ± 1.3 mmol/L (101.0 ± 49.2 mg/dL). At enrolment, 97.9% of patients were receiving a statin (25.3% on high intensity treatment). Only 32.1% of the very high risk patients versus 51.9% of the high risk and 55.7% of the moderate risk patients achieved their LDL-C goals. On multivariable analysis, factors independently associated with not achieving LDL-C goals were no (versus lower dose) statin therapy, a higher (versus lower) dose of statin, statin intolerance, overweight and obesity, female sex, neurocognitive disorders, level of cardiovascular risk, LDL-C value unknown at diagnosis, high blood pressure and current smoking. Diabetes was associated with a lower risk of not achieving LDL-C goals. Conclusions These observational data suggest that the achievement of LDL-C goals is suboptimal in selected countries outside Western Europe. Efforts are needed to improve the management of patients using combination therapy and/or more intensive LLTs.</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Jul</publication><modification>2025-04-04T19:40:19.765Z</modification><creation>2019-03-26T23:46:38Z</creation></dates><accession>S-EPMC6039862</accession><cross_references><pubmed>29771156</pubmed><doi>10.1177/2047487318777079</doi></cross_references></HashMap>